| INTRODUCTION
Lung cancer is the leading cause of cancer deaths in the US, with an estimated 224 210 new cancer cases and 159 260 deaths in 2014. 1 Surgery is more effective for the early-stage lung cancer without metastasis, when the tumor can be completely removed. Unfortunately, the disease is typically asymptomatic, until it is in the late stages, and the best chance for surgical treatment is usually lost. Consequently, the mortality is high: the 5-year survival rate for lung cancer is only 4.0% for patients with distant tumors, compared with 54.0% for patients with localized tumors. 2 Chest radiograph is a common approach for detecting lung cancer, but the annual screening with chest radiograph has not reduced lung cancer mortality, compared with usual care. 3 Although low-dose computed tomography (CT) screening is a promising method for detecting lung cancer in individuals at high risk, 4 ,5 the treatment is expensive, and it exposes patients to some extra doses of radiation.
Besides, the low-dose CT screening has been associated with a high rate of false positive results, with ∼95% of benign lung nodules that are challenging for radiologists to identify. 4 Therefore, there is still a demand for new less-invasive but more efficient biomarkers in the risk assessment and early detection of lung cancer.
Cancer cells often share the attributes of metabolic abnormalities, such as perturbation in the energy metabolism of glucose, glutamine, and lipids. 6, 7 Fatty acids (FAs), an important subgroup of lipids, have emerged as a recent focus of cancer research. FAs are synthesized de novo to continually provide lipids for energy production, cell membrane regeneration and lipid modification of proteins to meet the excessive bioenergetics and structural demands of highly proliferating cancer cells. Additionally, FAs and their derivatives are also important signaling molecules that may affect many fundamental cell processes, including cellular survival, proliferation, migration, angiogenesis, and therapy resistance. 8 Furthermore, the metabolites of FAs could augment survival [9] [10] [11] and enhance adhesion 12 in lung cancer cells, and thus promote progression and metastasis and induce angiogenesis in human lung cancer. [13] [14] [15] [16] More recently, increasing evidence suggests that the FAs are potential biomarkers for monitoring development and progression of lung cancer. [17] [18] [19] [20] For instance, in serum samples from 55 patients with lung cancer and 165 similar pulmonary patients without known cancer, Liu et al found that free FAs and their metabolites demonstrated good sensitivity and specificity for the identification of adenocarcinoma of the lung. 17 Similarly, other studies demonstrated that FAs from erythrocyte total lipids might be used as diagnostic biomarkers of lung adenocarcinoma, squamous cell carcinoma, and small cell lung cancer. 18, 19 Most recently, Zhang et al revealed that serum unsaturated free FAs could be used as potential biomarkers for early detection and disease progression of lung cancer. 20 Consequently, we hypothesized that genetic variants in genes involved in the FA synthesis, degradation, metabolism, and transport were potential susceptibility factors for lung cancer. 2 | METHODS AND MATERIALS
| Study populations and genotyping
The detailed information about the study participants is presented in Supplemental Table S1 , and all the participants were of European descendent. A written informed consent was obtained from each participant in the GWASs, and the present study followed the study protocols approved by the institutional review board for each of the participating institutions.
| Initial meta-analysis
The present study started from the combined genotyping and imputation dataset of six previously published GWASs of lung cancer from the TRICL consortium. Within the TRICL consortium, 21 12 160 lung cancer cases and 16 838 controls from Europe and North America participated in the GWASs. 22 All the cases and controls were at least frequency-matched on age and sex. The participants were described in 
| Gene and variant selection
To identify relevant genes of interest, we used two electronic databases, Gene Cards 29 and MSigDB 30 to search for FA metabolismrelated genes. Specifically, keyword searches using "fatty acid" in pathway & interaction section and "cancer" in disorder section in the Gene Cards and one heading "fatty acid" in the MSigDB. As a result, 317 genes located on autosomal chromosomes were identified from the FA biosynthesis, metabolism and degration pathways (Supplementary Table S2 and Fig. S1 ). Genotyped, imputed common SNPs (minor allele frequency ≥0.05) within these genes or their ±2 kb flanking regions were selected for association analysis. Hence, 30 722
SNPs in the FA metabolic pathways had been extracted from the TRICL GWASs and used for further analysis.
| Statistics
Meta-analysis was first performed among the six GWASs from the TRICL consortium. Briefly, the association between each SNP and lung cancer risk was assessed by unconditional logistic regression using an additive genetic model of the risk allele. The Cohran's Q statistic to test for heterogeneity and the I 2 statistic to quantify the proportion of the total variation due to heterogeneity were calculated. 31 Fixed-effects models were applied, when there was no heterogeneity among the datasets (based on the criteria P >0.10 and I 2 <25%); otherwise, randomeffects models were applied. 32 The Benjamini and Hochberg's false discovery rate (FDR) method was used for correction of the multiple comparisons. 33 Associations were considered significant, if an FDR value was less than 0.05. For the top-hit variants of interest, we then focused on those SNPs with potential functional as predicted by the online prediction tools: SNPinfo 25 and pfSNP. 34 Linear regression analysis was used to test expression quantitative trait loci (eQTL) associations with data obtained from the RNA sequencing project of the
Genomes Project samples conducted by Genetic European
Variation in Health and Disease Consortium (GEUVADIS). 35 Gene expression values that were more than three standard deviations from the mean were considered as outliers. 36 Finally, we tested the association between predicted functional SNP and lung susceptibility in the Harvard GWAS, 24 and subgroup analyses stratified by histology types (squamous and adenocarcinoma) and smoking status (smoker and non-smoker) were also performed. LocusZoom was used to produce regional association plots. 37 All statistical analyses were carried out by SAS software (version 9.1.3; SAS Institute, Cary, NC) or R (2.6.0) unless specified otherwise. The analysis flow chart is present in Fig. 1 .
| RESULTS
The six GWASs from the TRICL consortium consisted of 12 160 cases and 16 838 controls of European ancestry (Supplementary Table S1 ). S4 ). Gene expression differences among genotypes were examined using a regression model in which the association between gene expression and genotypes was considered additive, assuming that a trend by the number of variant alleles exists. As shown in Fig. 3 , the number of the variant A allele was shown to be associated with higher expression levels of CYP4F3 (P additive = 0.001), compared with the common G allele.
Therefore, we chose rs4646904 as the tagSNP of the CYP4F3 region. In the meta-analysis of the TRICL consortium, there was no heterogeneity observed among the six GWASs, with I 2 of 0 and the Qtest P value of 0.488. In combined analysis, we found that the per-unit increase of the variant A allele was associated with 1. ). For this analysis, we used a random-effects model, because the effect estimate displayed a moderate degree of heterogeneity with I 2 = 30.9% and the Q test P = 0.192 (Fig. 4) .
When stratified by lung tumor types, the combined effect was 1. 
| DISCUSSION
Deregulation of the FA metabolic pathways has been implicated in many cancers. [38] [39] [40] In the present study, we explored associations between genetic variants in the FA metabolic pathways and risk of lung cancer. We examined all typed and imputed SNPs of the genes involved in the FA metabolic pathways from six published GWASs of lung cancer within the TRICL consortium. We also tried to find additional support from the Harvard GWAS. In the meta-analyses of the TRICL GWASs, the predicted functional SNP, CYP4F3 rs4646904 G>A, showed a significant association with lung cancer risk, but this association was not significant in the Harvard Lung Cancer Susceptibility Study; however, this SNP remained significant in the final combined analysis as well as in subgroups of squamous cancer and smokers.
The CYP4F3 gene contains 14 exons and 13 introns and encodes a member of the cytochrome P450 superfamily of enzymes. The CYP4F3 pre-messenger RNA is spliced into two mature transcripts (ie, CYP4F3B and CYP4F3A). Human CYP4F3s are the main catalysts in the oxidation of FAs: they can ω-hydroxylate a variety of long chains and very long chains as well as saturated, unsaturated, and branched chain FAs, vitamins with long alkyl side chains, and the physiologically important prostaglandins and hydroeicosatetraenoic acids. 41 Additionally, the ability of CYP4F3 to ω-hydroxylate both pro-and found that rs4646904 might influence splicing efficiency of CYP4F3; SNPs in bold were putative functional and were not located in the major histocompatibility complex region.
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anti-inflammatory leukotrienes (ie, LTB4) indicates that they may function in both the activation and resolution phases of the inflammatory response. 42 The CYP4F3 rs4646904 G>A variant was a novel, potentially functional SNP that had the smallest P value in the present meta-analysis of the TRICL GWASs. Although CYP4F3 rs4646904 G>A is a synonymous variant, it is located within an exon splicing enhancer (ESE), 25 which has discrete sequences within exons that promote both constitutive and regulated splicing. 43 Efficient splicing has limited tolerance of mutations in the ESEs, even if they have no effect on protein coding. 44 Additionally, ChIP-seq data indicate that rs4646904 is located in the enhancer region containing histone modification marks of H3k09me3, H3k27me3, and H3k09me3. 45 Cigarette smoking is the major cause of cancers of the respiratory tract, and CYP4F3 was found to be up-regulated in human airway epithelium in healthy current smokers, compared with those of never smokers, [46] [47] [48] which suggests that CYP4F3 may be induced by smoking and thus contributes to carcinogenesis. The finding that the rs4646904 A variant allele was associated with significant higher gene expression levels than the G allele is consistent with the findings in other cancers, in which unregulated expression levels of CYP4F3s
were found in pancreatic ductal adenocarcinoma, compared to benign lesions, 49 as well as related with hepatocyte differentiation status 50 and progression of HCV-associated hepatocellular carcinoma. 51 Despite the underlying biological plausibility supporting this lung cancer-associated rs4646904 in the meta-analysis of the TRICL consortium with 12 160 cases and 16 838 controls, the relatively small
Harvard GWAS dataset with 984 cases and 970 controls did not provide a further support for the association, but the combined metaanalysis revealed a slight effect with P < 0.05. Nevertheless, according to a PASS 52 power calculation, the Harvard GWAS had a mere power of 0.18 to detect an OR of 1.1. In contrast, the combined meta-analysis of the TRICL and Harvard GWASs with a total of 13 144 cases and 17 808 controls achieved a power of 0.98 for detecting an OR of 1.1, which suggest that rs4646904 may have a very small but genuine effect on lung cancer risk. Interestingly, the rs4646904-cancer risk association was significant in subgroups with squamous cancer and smokers but not adenocarcinoma and non-smokers, and there were high heterogeneity among the results of these subgroups, indicating that there might be an interaction between smoking and rs4646904. 53 It may be because the exposure to cigarette smoke negatively affect the synthesis of n−3 long-chain polyunsaturated fatty acid from the precursor in mammary gland cells. 54 Hence, rs4646904 might be biomarker for lung cancer risk in smokers.
It should be noted that there were limitations of the present study. First, none of the CYP4F3 variants was identified in previous TRICL GWASs as significant at a GWAS threshold (P < 10 −7 ). Indeed, recent GWASs have identified at least 10 independent loci, and, as a result, only a small fraction of heritability could be explained by these SNPs. The challenge remains to identify the many additional common risk loci that are expected to have smaller genetic effects. 55 The pathway-based analysis, such as in the present study, reduces the significance level of P values based on the number SNPs 
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